8 Speculative Stocks That Could Rise 100% to 300%
Oppenheimer feels that FuelCell Energy continues to execute well, while it is limiting its cash burn and delivering product on time. And gross margin is improving while the company is also building a project pipeline in North America and accelerating its equipment sales in Asia. Oppenheimer believes that all that and the recently passed extension of the investment tax credit are helping move FuelCell toward positive operating cash flow. Its contract backlog is nearly $640 million at this point.
FuelCell Energy has a 52-week trading range of $0.80 to $2.49 and a market cap of roughly $140 million. Its consensus target price is roughly $3.50, but that is from a very small group of analysts.
Genocea Biosciences Inc. (NASDAQ: GNCA), which is targeting develops novel cancer vaccines, was given two huge upside calls this week. H.C. Wainwright started it with a Buy rating and a $5 price target (versus a $1.11 close). Earlier in the week, Cantor Fitzgerald assigned an Overweight rating and a similar $5 target (versus a $1.03 close).
The positive themes around each call were on the notion that personalized therapies will be among the next big things, and a recent cash raise in January helped bolster its books.
Genocea Biosciences was trading at $1.17 later in the week and closed up almost 4% at $1.24 on Friday, in a 52-week range of $0.79 to $7.29. It has a mere $102 million market cap.
Intellia Therapeutics Inc. (NASDAQ: NTLA) was started as Market Outperform with a $76 price target at JMP Securities on March 8. This was more than 100% upside from the prior $29.43 closing price, but the shares were up 8% at $31.95 after the analyst call was made.
Intellia’s 52-week range is $11.15 to $33.34, so a lot of the big upside already may have been seen by some of the other analysts who cover this $1.35 billion company.
Plug Power Inc. (NASDAQ: PLUG) was reiterated as Buy with a $5 price target at Canaccord Genuity, which noted that the recently passed extension of the investment tax credit invites improvement, as well as a new North American retailer coming on board. This represented more than 150% upside, despite a small disappointment on earnings.
Plug Power was trading at $1.95 late in the week, in a 52-week range of $0.92 to $3.21.
Revance Therapeutics Inc. (NASDAQ: RVNC) was started with a Buy rating and assigned a $60 target at Goldman Sachs. That compares with a prior close of $31.30 and a $32.75 price late in the week. It is almost unheard of for Goldman Sachs to issue such optimistic upside.
Piper Jaffray issued a more conservative price target of $48, which still implied upside of more than 50% at the time. Revance is targeting the development and commercialization of novel botulinum toxin products for various aesthetic and therapeutic indications.
Revance has a post-IPO trading range of $18.00 to $32.75, so it already has been quite volatile. The company has a $1.2 billion market value.
Turtle Beach Corp. (NASDAQ: HEAR) has been around for a while and makes headsets for video gaming and entertainment systems. It is also tiny, with a $24 million market cap. Turtle Beach was reiterated as Outperform with a $1.50 price target at Wedbush Securities this week. The firm pointed to anticipated revenue growth and further gross margin expansion as allowing the company to increase profitability while reinvesting in growth opportunities.
This call for Turtle Beach now represents more than 200% upside from the $0.48 closing price on Friday, but its stock was at $0.56 ahead of the analyst call. That may not be the best price action and may be just one more flag for investors looking at a rather speculative company. Turtle Beach has a 52-week range of $0.41 to $1.12.
A group of candlestick charts from StockCharts.com is included below. This shows the 60-day performance of each of the eight speculative stocks named in this report. Charts for the key exchange traded funds have been shown as well: NASDAQ 100 (QQQ), Dow (DIA), S&P 500 (SPY) and the S&P Small Cap 600 ETF (VIOO).